Precipio, Inc. (PRPO)
NASDAQ: PRPO · Real-Time Price · USD
14.46
+0.20 (1.40%)
Aug 1, 2025, 4:00 PM - Market closed
Company Description
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.
It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.
It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Precipio, Inc.
| Country | United States |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Ilan Danieli |
Contact Details
Address: 4 Science Park, 3rd Floor New Haven, Connecticut 06511 United States | |
| Phone | 203 787 7888 |
| Website | precipiodx.com |
Stock Details
| Ticker Symbol | PRPO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001043961 |
| CUSIP Number | 74019L503 |
| ISIN Number | US74019L6020 |
| Employer ID | 91-1789357 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Ilan Danieli | Founder, President, Chief Executive Officer and Director |
| Ahmed Zaki Sabet | Chief Operating Officer |
| Dr. Ayman A. Mohamed M.D. | Chief Technology Officer |
| Matthew Gage | Chief Financial Officer |
| Miri Chiko-Radomski | Chief Legal Counsel and People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | 8-K | Current Report |
| Jun 17, 2025 | 8-K | Current Report |
| Jun 16, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 15, 2025 | 8-K | Current Report |
| May 14, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2025 | 8-K | Current Report |